Stock Performance and Market Context
On 2 July 2026, KIMS’s share price surged to Rs.842, surpassing its previous 52-week high of Rs.840. This rise represents a 1.82% gain on the day, outperforming the Sensex, which advanced by 0.57%. The stock also outperformed its hospital sector peers by 0.87% on the same day, underscoring its relative strength within the industry.
The stock has demonstrated consistent upward momentum, recording gains over the last four consecutive trading sessions. During this period, KIMS delivered a cumulative return of 5.59%, signalling robust investor confidence and positive market sentiment. The stock’s trading range remained narrow at Rs.6.75, indicating steady price movement without excessive volatility.
Long-Term Returns and Comparative Analysis
Krishna Institute of Medical Sciences Ltd’s performance over various time horizons has been impressive when compared to the broader market. Over the past year, the stock appreciated by 26.25%, while the Sensex declined by 7.25%. Year-to-date, KIMS has surged 39.33%, contrasting with the Sensex’s negative return of 9.22%.
Looking further back, the stock’s three-year return stands at 137.12%, significantly outpacing the Sensex’s 19.53% gain. Over five years, KIMS’s price appreciation has been even more remarkable at 316.06%, compared to the Sensex’s 47.40%. These figures highlight the company’s strong growth trajectory and resilience in the hospital sector.
Technical Indicators and Trend Analysis
The technical outlook for KIMS remains bullish. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals sustained upward momentum. The current trend was confirmed as bullish on 2 June 2026, when the stock price was at Rs.746.55, marking a shift from a mildly bullish phase.
Key technical indicators present a mixed but predominantly positive picture. Weekly MACD and Bollinger Bands are bullish, while the monthly MACD is mildly bearish. The Relative Strength Index (RSI) shows bearish signals on a weekly basis but no clear monthly trend. Other indicators such as the KST and Dow Theory remain bullish on the weekly scale, supporting the overall positive technical stance.
Immediate support for the stock is identified at Rs.575.55, the 52-week low, while resistance levels include Rs.789.33 (20-day moving average area), Rs.708.10 (100-day moving average), and Rs.694.38 (200-day moving average). The all-time high of Rs.840 represents a strong resistance level that the stock has now surpassed.
Valuation Metrics
At the current price of approximately Rs.845.90, KIMS trades at a price-to-earnings (P/E) ratio of 141 times trailing twelve months earnings, reflecting a premium valuation consistent with growth-oriented stocks in the hospital sector. The price-to-book value stands at 15.57 times, while enterprise value multiples include EV/EBITDA at 48.81 times and EV/EBIT at 75.45 times. The EV/Sales ratio is 10.03 times, and EV/Capital Employed is 6.11 times.
Dividend metrics are not applicable as the company has not declared dividends recently, with dividend yield and payout ratios marked as not available.
Quality Assessment and Financial Health
KIMS is classified as a good quality company based on its long-term financial performance. The management risk is rated as good, with a capital structure also deemed sound. Growth metrics are below average, but the company has maintained a healthy sales compound annual growth rate (CAGR) of 24.04% over five years and an EBIT growth of 11.48% in the same period.
Return on capital employed (ROCE) averages a strong 20.10%, while return on equity (ROE) is a respectable 17.81%. Institutional holdings are high at 47.07%, indicating significant participation by large investors. The company carries moderate leverage, with an average debt to EBITDA ratio of 2.15 and net debt to equity of 1.85, reflecting a balanced approach to financing.
Recent Financial Trends
Quarterly financial data shows that KIMS achieved its highest net sales at ₹1,074.60 crores and a peak PBDIT of ₹206.50 crores. However, some short-term financial indicators have shown softness, including a lower operating profit to interest ratio of 3.03 times and a reduced ROCE of 8.42% in the half-year period. The debt-equity ratio rose to 1.89 times, and inventory turnover ratio declined to 40.30 times. Profit before tax excluding other income and net profit after tax also recorded lower quarterly figures at ₹56.00 crores and ₹49.08 crores respectively, with earnings per share at ₹1.06.
Despite these short-term fluctuations, the company’s overall quality and long-term growth remain intact, supported by strong institutional backing and a solid market position.
Volume and Trading Activity
Delivery volumes have shown a recent increase, with a 1-day delivery change of 53.62% compared to the 5-day average. Over the trailing month from 1 June to 1 July 2026, delivery volumes averaged 3.91 lakh shares, slightly lower than the previous month’s average of 4.07 lakh shares. On 1 July 2026, delivery volume was 1.57 lakh shares, representing 41.19% of total volume traded that day.
Conclusion
The attainment of an all-time high price of Rs.842 by Krishna Institute of Medical Sciences Ltd on 2 July 2026 marks a significant achievement in the company’s market journey. Supported by strong relative performance against the Sensex and sector benchmarks, a bullish technical trend, and solid long-term financial quality, the stock’s milestone reflects the company’s sustained growth and market confidence. While some short-term financial metrics indicate areas of softness, the overall outlook remains positive, with the stock trading above key moving averages and maintaining strong institutional interest.
